We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Optibiotix Health Plc | LSE:OPTI | London | Ordinary Share | GB00BP0RTP38 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.25 | 1.45% | 17.50 | 17.00 | 18.00 | 17.50 | 17.25 | 17.25 | 120,641 | 08:06:20 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Noncomml Resh Organizations | 457k | 2.59M | 0.0284 | 6.16 | 15.96M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/1/2019 18:28 | Updated (growing) list:Current and future revenue streams confirmed so far:- GoFigure: shakes, bars and muesli pots - CholBiome (x3 and Daily Maintenance)- Sacco/CSL- HLH BioPharma Vertriebs GmbH - Nutrilinia (LD-LDL and Slimbiome Medical)- Pharmabiota- Galenicum Special Ingredients - Knighton Foods- Cereal Ingredients Inc.- Fine Foods & Pharmaceuticals- Trigen Pharma- Cambridge Commodities - Akums Drugs and Pharma- Seed Health- John Morley's - Alfasigma- Unnamed global corporate ($100B+ turnover) for SweetBiotix manufacturing & distribution.- Unnamed US pharma partner (cholesterol strain)- Bened Biomedical- Bulgarian CholBiome distributor (thought to be Velinoff Pharma)- CTC Group- Formulation Creations- US Pharma Lab Inc.- Unnamed Greece and Cyprus CholBiome distributor- Unnamed Greece and Cyprus SlimBiome Medical distributor - Zeon Lifesciences Revenue not confirmed yet:- Tata X 2 (Slimbiome and LPGOS)- Mystery US Slimbiome customer- Paradise Fruits (Slimbiome)- Beijing Duoite Biotechnology Co., Ltd (LP-LDL distributors via CSL)Products on the market (already or soon) but not RNSed:- MuscleForm (Aviform Ltd) - Ultra MR Ultimate Meal Replacement - Olliscience - Ollibiotic- SilvExpo - RSM CardioPro and CholBiome - Aragan - BioticP3 | parob | |
07/1/2019 18:10 | SOH has said potential deal in China, ProBiotix IPO this year and given a clear direction of travel for the next year or so. It is positive and perhaps doubters should listen to that interview once more. | rafboy | |
07/1/2019 17:36 | Judi, if I had a pound for every time I've heard the word transformational, I would be as wealthy as some of the peeps on this board! | dazah | |
07/1/2019 17:24 | Good interview from Mr OH All lining up nicely for the genuine and patient long termers Transformational couple of years from now on in imho | judijudi | |
07/1/2019 17:08 | Not as strong finish as I'd have liked. Overall feeling..."meh" | dazah | |
07/1/2019 16:53 | hTTps://mobile.twitt | parob | |
07/1/2019 16:10 | Look at SBTX today! | dazah | |
07/1/2019 16:03 | https://www.proactiv | riskybusiness1 | |
07/1/2019 16:02 | New SOH Interview just outOptiBiotix's SlimBiome gathers steam as subsidiary eyes potential IPO15:52 07 Jan 2019Life sciences firm OptiBiotix Health plc (LON:OPTI) has clinched a number of deals for its SlimBiome weight loss product as the company eyes up a potential initial public offering (IPO). Founder and CEO Stephen O'Hara tells Proactive London how OptiBiotix is changing from an R&D company to a business with greater commercial focus with a number of new deals in 2019 and our prodcuts migrating into other territories.The group has just inked an agreement with Indian firm Zeon Lifesciences Ltd, granting it an exclusive licence to manufacture and supply SlimBiome in the return in return for a 50% share of the profits.hTTps://tiny | parob | |
07/1/2019 15:24 | sbtx starting to move now up 10% | manc10 | |
07/1/2019 14:34 | velinoff Pharma A Natural Way for Better Heart Health! Posted on 07.01.2019 by velinoff Cardiovascular diseases (GCC) are the leading cause of death worldwide, with cholesterol being a major factor. Cholesterol is needed to build up cells and hormones, but excessive amounts are associated with an increased risk of GCC. Of the two major forms of cholesterol, LDL (Low Density Lipoprotein) is responsible for obstruction of the arteries, which can lead to GCC, while HDL (high density lipoprotein) helps to clear cholesterol from the blood. Therefore, it is important not only to maintain healthy levels of total cholesterol but also a good ratio of HDL to LDL. Restricting cholesterol intake is important. However, since the liver naturally produces significant amounts of cholesterol, and complete elimination from food is impossible, additional measures are recommended. CholBiome ® X3 is the perfect solution. The Natural Way for Better Heart Health! CholBiome ® X3 is a last generation product of the Live Biotherapeutic Products group (LBP) combining three natural ingredients that help maintain healthy cholesterol levels. CholBiome ® X3 is supported by clinical trials and guarantees cardiovascular risk prevention. CholBiome ® X3 strengthens the Cardiovascular System, naturally reducing cholesterol levels, lowering blood pressure, and reducing Cardiovascular Risk. Mechanism of action: CholBiome ® X3 works by changing the existing microbial - the natural intestinal flora of the individual to offer a natural, scientifically-based solution without side effects. CholBiome ® X3 is an LBP therapeutics combining proven ingredients Monoclin K from red rice, Vitamin B3 (niacin) and patented Lactobacillus plantarum LPLDL ® : - Lactobacillus plantarum LPLDL ® is a patented strain of OPTIBIOTIX HEALT Plc - a naturally occurring bacterium that acts by interrupting cholesterol recirculation in the body by ejecting unnecessary amounts of harmful cholesterol. In this way, the liver withdraws its blood cholesterol synthesis needed for the synthesis of bile salts, reducing its amount in the cardiovascular system. Lactobacillus plantarum LPLDL ® has an excellent ability to modulate the metabolism of bile acids. It has a positive benefit for heart health and factors such as high blood pressure and high cholesterol, as well as other processes from liver function to glucose regulation and vitamin metabolism. - Monocoline K of red rice - inhibits cholesterol synthesis in the liver and maintains normal levels of cholesterol in the blood. It is a natural product obtained by the fermentation of yeast rice Monascus purpureus, a traditionally used medium for high cholesterol. - Vitamin B3 (niacin) - modulates the degradation of fat in the cell, helping to maintain normal metabolism. Clinical studies demonstrating the efficacy and safety of LPLDL ® : Reduces total cholesterol by up to 36.7% Reduces LDL cholesterol by up to 13.9% Increases HDL cholesterol by up to 4.5% Reduces systolic blood pressure by 5.1% Fully safe *, well tolerated and without known side effects! * compared to statins Composition: Patented bacterial strain Lactobacillus plantarum LPLDL ® - 4.10 9 CFU Monocoline K - 10 mg Vitamin B3 - 16 mg Dosage: Adults per 1 capsule daily in the morning on an empty stomach Expected results: after the first month Course of therapy: minimum 3 months | scotty1 | |
07/1/2019 14:19 | Ceo indicates revenues are up 5-6x in the H2 2018 compared to H1. Business achieved break even on a month to month before YE as was stated along with an expectation to push the company into overall profitability this year.Another words these agreements are becoming fruitful and will keep on growing along with new partners, territories, products, applications and profits | riskybusiness1 | |
07/1/2019 14:14 | Buywell3. You could always invest your money in UKOG. | jamesrs1 | |
07/1/2019 14:12 | BW, if you read the lemming blog there are 'revenue bearing' deals, or turnover if that is what you want to call it. Look at the red text. | slartybartfaster | |
07/1/2019 14:06 | Lots of signed agreements ... but no turnover ... no sales | buywell3 | |
07/1/2019 14:01 | From 8p to 96p in a little over four years. That’s a 12x increase. With everything that’s happening now and so many things to come in the near future,can it go 3x from here in the next three years. Company director locked in until double the price from 80p. Obesity being a worldwide problem. I can’t see anything better out there for myself to be invested in. Massive respect for research and information posted by The true Believers that always reconfirm my reason for being invested here. | jamesrs1 | |
07/1/2019 13:59 | 'We believe partnering with Zeon is an important step in optimising the supply chain to facilitate the needs of EXISTING and new corporate partners in India and Southern Asia and anticipate FURTHER announcements in due course.'SOH executing the model & strategy phenomenally. The scalability & profitability potential really is mind blowing. Usually FCAP are useless but that piece posted by Sum is very interesting as it highlights manufacturers in the key markets (though doesn't mention Sacco); Europe, US & Asia. I find it incredible how they are able to negotiate profit share agreements in each. Not only signing tons of agreements but sequentially aligning them in each territory in order to set up a complete supply chain where Optibiotix license its technology to each level of the chain. All goes straight to the bottom line whilst costs remain tightly controlled. | riskybusiness1 | |
07/1/2019 13:52 | dazah - Thank you for your apology. If you can see your way to editing your original post, more befitting to what you truly intended to portray, I can remove my rantings and allow us to clear the air and allowing me to apologize to you for the misunderstanding. TIA Or was this a cunning ruse to draw me out from under my bushel? ;-) | elrico | |
07/1/2019 12:59 | Well elrico we do appreciate your writings and apologies if there was a misunderstanding. | dazah | |
07/1/2019 12:57 | 8p to 94p spiking to £1.33 over a 4 year period looks pretty stable and progressive to me?If you want stability you should stick clear of AIM and head for blue chip stocks, though even they've been more volatile than usual the past year. | riskybusiness1 | |
07/1/2019 12:56 | "Even elrico in one of his blogs gave a nod to TWs advice to top slice." I only see one way of reading the above line, and that is to suggest I agreed with TW's advise to "top slice." I did not agree at the time but concede it was correct. Why else use me and the blog!! End of discussion as far as I am concerned. | elrico | |
07/1/2019 12:53 | That's correct Charlie. | dazah | |
07/1/2019 12:52 | What is this? I've always said that I'm positive on OPTI I even buy lots of their products. That is not withstanding frustrations I have as notwithstanding the very wealthy investors here aka the LTHs I'm sure in the share price decline from 133p to 60-odd pence we lost a lot of PIs making losses. And so as I have said SOH should do his best to keep a sensible share price ship whilst we all appreciate and believe in the long term vision for OPTI. | dazah | |
07/1/2019 12:49 | I'm going to go out on a limb and suggest he was referencing elricos mentioning of TW's sell recommendation in a negative light when I said gave a nod to it. I doubt he was suggesting elrico endorsed the top slicing. | charlieej |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions